Senti Biosciences Stock
Senti Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Timothy K. Lu
- Employees
- 39
- Market cap
- $7 M
- IPO
- 26/05/2021
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues,…
Senti Biosciences stock: price history
1D
-14.0%
1W
-28.5%
1M
-27.8%
6M
-79.6%
YTD
-78.4%
1Y
-89.7%
2Y
-89.7%
5Y
-99.8%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~29% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Senti Biosciences
Analyst assessment of Senti Biosciences
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.00
MEDIAN
US$6.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
2
BUY
2
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 15/05/2026
Senti Biosciences stock metrics
P/E
-0.13
P/B
-2.06
EV/EBITDA
-0.44
RETURN ON EQUITY
374.9%
NET MARGIN
-75,000.0%
DEBT/EQUITY
-5.95
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
39.4%
FLOAT SHARES
12,284,114
AVG. DAILY VOLUME (30D)
1,598,377
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Senti Biosciences stock
What does Senti Biosciences do?
Senti Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Timothy K. Lu, the company employs around 39 people.
The IPO was on 26/05/2021; the stock trades on NASDAQ under the ticker SNTI.
What do analysts say about Senti Biosciences stock?
4 analysts rate the stock, the consensus is Buy (as of 15/05/2026).
The average price target is US$6.00, ranging from US$6.00 to US$6.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Senti Biosciences report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -29% stronger than usual.
Does Senti Biosciences pay a dividend?
No, Senti Biosciences currently does not pay a dividend.
Which stocks are comparable to Senti Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Senti Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Senti Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.